The Mumbai-based drug maker’s profit rose to 1.46 billion rupees ($17.86 million) in the three months ended March 31, from 989 million rupees in the year-ago quarter, the company said in a regulatory filing. The company, spun off from Glenmark Pharmaceuticals Ltd in 2019 to focus on the API business, said total revenue from operations jumped nearly 21 per cent to 6.21 billion rupees in the quarter., The Mumbai-based drug maker’s profit rose to 1.46 billion rupees ($17.86 million) in the three months ended March 31, from 989 million rupees in the year-ago quarter, the company said in a regulatory filing. The company, spun off from Glenmark Pharmaceuticals Ltd in 2019 to focus on the API business, said total revenue from operations jumped nearly 21 per cent to 6.21 billion rupees in the quarter., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way